These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10188630)

  • 1. Kinetic analysis of GM1 effects on haloperidol-induced dopaminergic supersensitivity.
    Palermo-Neto J; Frussa-Filho R; Vital MA
    Gen Pharmacol; 1999 Feb; 32(2):265-70. PubMed ID: 10188630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover.
    Vital MA; Flório JC; Frussa-Filho R; De Lucia R; Tufik S; Palermo-Neto J
    Life Sci; 1998; 62(13):1161-9. PubMed ID: 9519797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
    Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monosialoganglioside increased the in vivo affinity of D2 receptors for apomorphine in supersensitive rats.
    Vital MB; Frussa-Filho R; Palermo-Neto J
    Ann N Y Acad Sci; 1998 Jun; 845():428-9. PubMed ID: 9668390
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of monosialoganglioside on dopaminergic supersensitivity.
    Vital MA; Frussa-Filho R; Palermo-Neto J
    Life Sci; 1995; 56(26):2299-307. PubMed ID: 7791517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of striatal glutamatergic system in haloperidol-induced dopamine receptor supersensitivity and effects of monosialoganglioside GM1.
    Schroeder H; Schroeder U; Sabel BA
    Pharmacol Biochem Behav; 1997 Dec; 58(4):903-7. PubMed ID: 9408194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
    Schröder U; Schröder H; Augustin W; Sabel BA
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of buspirone on dopaminergic supersensitivity.
    Queiroz CM; Frussa-Filho R
    Life Sci; 1997; 61(4):371-82. PubMed ID: 9244363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of central nervous system supersensitivity induced in rats by long-term haloperidol administration. I. pA2 determination.
    Palermo-Neto J; Bernardi MM; Saban R
    Pharmacology; 1984; 28(4):203-10. PubMed ID: 6539476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of melatonin on behavioral dopaminergic supersensitivity.
    Abílio VC; Vera JA; Ferreira LS; Duarte CR; Martins CR; Torres-Leite D; Ribeiro Rde A; Frussa-Filho R
    Life Sci; 2003 May; 72(26):3003-15. PubMed ID: 12706487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural subsensitivity induced by long-term administration of a low dose of haloperidol to rats.
    Frussa-Filho R; Abílio VC; Bergamo M; Palermo-Neto J
    J Pharm Pharmacol; 1997 Apr; 49(4):412-5. PubMed ID: 9232539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats.
    Andreassen OA; Jørgensen HA
    Psychopharmacology (Berl); 1994 Dec; 116(4):517-22. PubMed ID: 7701057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
    Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
    Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.
    Glenthøj B
    Psychopharmacology (Berl); 1993; 113(2):157-66. PubMed ID: 7855176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal synaptophysin levels are not indicative of dopaminergic supersensitivity.
    Marin C; Tolosa E
    Neuropharmacology; 1997 Aug; 36(8):1115-7. PubMed ID: 9294977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation.
    Marin C; Chase TN
    Eur J Pharmacol; 1993 Feb; 231(2):191-6. PubMed ID: 8095897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.